Last10K.com

Anika Therapeutics, Inc. (ANIK) SEC Filing 8-K Material Event for the period ending Thursday, June 24, 2021

Anika Therapeutics, Inc.

CIK: 898437 Ticker: ANIK
0000898437 false 0000898437 2021-06-24 2021-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 24, 2021

 

Anika Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

____________________

 

Delaware  000-21326  04-3145961
(State or other jurisdiction of incorporation or organization)  Commission file number  (I.R.S. Employer Identification No.)

 

32 Wiggins Avenue, Bedford, MA 01730

(Address of principal executive offices) (Zip code)

 

(781) 457-9000

Registrant’s telephone number, including area code

 

Not applicable

(Former name or former address, if changed since last report)

____________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   ANIK   NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 8.01.Other Events.

 

On June 24, 2021, the Company achieved a regulatory milestone under the Merger Agreement executed between the Company and Arthrosurface, Incorporated on January 4, 2020, triggering a $10.0 million contingent consideration payment which the Company will pay in accordance with the terms of the Merger Agreement.

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 Anika Therapeutics, Inc.
  
  
Date: June 30, 2021By: /s/ Cheryl R. Blanchard
   Cheryl R. Blanchard
   President and Chief Executive Officer

 

 

View differences made from one to another to evaluate Anika Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anika Therapeutics, Inc..

Continue

Assess how Anika Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anika Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: ANIK
CIK: 898437
Form Type: 8-K Corporate News
Accession Number: 0001171843-21-004630
Submitted to the SEC: Wed Jun 30 2021 5:15:18 PM EST
Accepted by the SEC: Wed Jun 30 2021
Period: Thursday, June 24, 2021
Industry: Surgical And Medical Instruments And Apparatus
Events:
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anik/0001171843-21-004630.htm